Fennec Pharmaceuticals Inc. FENC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +32.99%
- 1 year
- +22.93%
- Open
- 10.92
- Prev close
- 10.95
- Mkt cap
- 359.09M
- Vol
- 195.65K
- Avg vol
- 187.92K
- EPS
- -0.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.14
- High
- 10.99
- Forward P/E
- 16.78
- Beta
- 0.27
- Short ratio
- 13.06
- Inst. own
- 54.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.08
- 200-d avg
- 6.71
- 1y target
- 13.60
News
2 weeks ago defenseworld.net
Adherex Technologies Inc. (NASDAQ:FENC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One investment analyst…
1 month ago defenseworld.net
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey
Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
1 month ago globenewswire.com
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
-
2 months ago benzinga.com
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
2 months ago zacks.com
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
2 months ago seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year…
2 months ago zacks.com
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
-
2 months ago benzinga.com
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of…
2 months ago globenewswire.com
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the…
2 months ago defenseworld.net
Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company,…
3 months ago zacks.com
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
4 months ago globenewswire.com
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
4 months ago globenewswire.com
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
4 months ago globenewswire.com
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy…
5 months ago marketbeat.com
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.
5 months ago globenewswire.com
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
5 months ago globenewswire.com
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
5 months ago seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow…
5 months ago benzinga.com
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
5 months ago zacks.com
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a…
5 months ago globenewswire.com
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~…
-
6 months ago benzinga.com
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.
-
6 months ago benzinga.com
Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~~ This New Study and Other Independent,…
-
7 months ago benzinga.com
Fennec Pharmaceuticals Q4 GAAP EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over…
-
7 months ago benzinga.com
Earnings Scheduled For March 24, 2026
Earnings Scheduled For March 24, 2026
7 months ago benzinga.com
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
-
7 months ago benzinga.com
Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the…
-
8 months ago benzinga.com
Fennec Pharma Backs Real-World Study Of PEDMARK To Protect Hearing In Cancer Patients
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the…
-
9 months ago benzinga.com
Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18
Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
11 months ago benzinga.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
11 months ago benzinga.com
Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan
Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of…
-
11 months ago benzinga.com
Reported Earlier, Fennec Pharmaceuticals Prices Offering Of 4,666,667 Common Shares At $7.50 Per Share For ~$35M In Gross Proceeds
Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness and the remaining net proceeds, if any, for working capital and general corporate purposes.
-
11 months ago benzinga.com
Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from…
-
11 months ago benzinga.com
Fennec Pharmaceuticals Plans To Launch Common Stock Offering; Terms Not Disclosed
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an…
-
1 year ago benzinga.com
Earnings Scheduled For August 14, 2025
Earnings Scheduled For August 14, 2025
1 year ago benzinga.com
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir…
-
2 years ago benzinga.com
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.